<DOC>
	<DOC>NCT01418963</DOC>
	<brief_summary>This two-part, randomized, double-blind, placebo-controlled study will assess the safety, pharmacokinetics and pharmacodynamics of single and multiple ascending oral doses of RO5285119 in healthy volunteers. Anticipated time on study will be up to 9 weeks for each subject.</brief_summary>
	<brief_title>A Study of RO5285119 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male adults, 18 to 45 years of age (Part 1) or healthy male or female adults, 18 to 65 years of age (Part 2) Body mass index (BMI) 18.0 to 30.0 kg/m2 inclusive Female subjects must be surgically sterile or postmenopausal Male subjects must use a barrier method of contraception for the duration of the study and for the three months after the last dosing History or presence of any significant disease or disorder Positive for hepatitis B. hepatitis C or HIV infection History of drug or alcohol abuse or suspicion of regular consumption of drugs of abuse Participation in an investigational drug or device study within 3 months prior to first dosing Donation of blood within 3 months prior to first dosing Regular smoker (&gt;5 cigarettes, &gt;3 pipefulls, &gt;3 cigars per day) History of hypersensitivity or allergic reactions Part 2: Contraindications for MRI scans</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>